Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis
- Written by PR Newswire
![]() |
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases, today announced positive results from a Phase III study – QUARTZ3 (NCT04875169)evaluating the efficacy and safety of once daily Ivarmacitinib as monotherapy in...